June 29, 2023

News Release

Company name:TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive
Officer(Securities code: 4891; Growth Market)

TMS Co., Ltd. entered into Joint Research Agreement withthe Microbial Chemistry Research Foundation
TMS Co., Ltd. (the “Company”) announces today that the Company has completed the process for entering intoa Joint Research Agreement with the Microbial Chemistry Research Foundation (the “MCRF”) on compound
discovery. The agreement was made effective on June 23, 2023.
As part of its efforts towards pipeline expansion, the Company is searching for new drug candidates utilizing
multiple approaches, including AI-based compound generation. In the Joint Research with the MCRF, theCompany intends to discover naturally derived compounds against the targets of Company’s interest by
screening the microorganism library as well as compound libraries provided by the MCRF. The Company
expects that the Joint Research may contribute to expansion of its pipeline in the future.
Since this initiative is in the exploratory stage, the impact on the Company's business performance for the current
fiscal year is expected to be minimal.
About MCRF
The foundation was established in 1958 from the proceeds of the patent of Kanamycin discovered by Dr. Hamao
Umezawa. The foundation promotes research activities with the aim of conducting research on microorganisms,discovering a wide range of beneficial substances, and developing and utilizing them to contribute to theprevention and treatment of disease, and thereby promote the health and welfare of the people. In particular, thefoundation focuses on the development and research of novel biologically active substances (antibiotics, anticancer drugs, and other drugs for the treatment of diseases, etc.) by utilizing its own natural product library andstrain library. In the Nature Index 2018 Japan, the foundation was ranked as the No. 1 Japanese research institutewhich published the highest percentage of high-quality scientific papers in the field of natural science.
For more information about the foundation, please visit the website at https://www.bikaken.or.jp/.
About TMS Co., Ltd.
TMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative
medicines for the treatment of serious diseases to address medical unmet needs. The Company’s pipeline
consists of a family of small compounds called SMTPs (Stachybotrys microspora triprenyl phenols) derived
from a fungus. The lead pipeline compound, TMS-007, is indicated for the treatment of acute ischemic stroke.
It demonstrated efficacy and safety in the completed Phase 2 study and was acquired by Biogen in 2021. Another
SMTP compound, TMS-008, is under development for acute kidney injury and other potential indications. Inaddition, the Company is exploring new pipeline products by focusing on early-stage seeds from academic
institutions in Japan, with the intention to build a bridge between academic discoveries and the global
pharmaceutical market. For more information about TMS, please visit https://www.tms-japan.co.jp/.
Note: This document has been translated from a part of the Japanese original for reference purposes only. In theevent of any discrepancy between this translated document and the Japanese original, the original shall prevail.
Investor and Media Contact:
ir@tms-japan.co.jp
End